Soleus Capital Management
Soleus Capital Management reported 97 stocks worth $2.8B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are KRYS (13.5%), PODD (8.0%) and NVCR (5.3%). Compared with Q2 2026, the fund opened new positions in ZLAB, KOD and INBX, added to KRYS, PODD and UTHR, trimmed NVCR, TGTX and CELC and sold out of GMED, SUPN and LIVN.
Latest filing: what Soleus Capital Management did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() KRYS Krystal Biotech Inc | $379M | 13.5% | 1.1M | +200K (+21%) | 8 of 8 | |
| 2 | ![]() PODD Insulet Corp | $225M | 8.0% | 1.7M | +678K (+65%) | 4 of 8 | |
| 3 | ![]() NVCR Novocure Ltd | $150M | 5.3% | 9.4M | −488K (−5%) | 8 of 8 | |
| 4 | ![]() TGTX TG Therapeutics Inc | $143M | 5.1% | 2.6M | −372K (−13%) | 8 of 8 | |
| 5 | ![]() UTHR United Therapeutics Corp Del | $140M | 5.0% | 259K | +33K (+15%) | 8 of 8 | |
| 6 | ![]() CELC Celcuity Inc | $134M | 4.8% | 1.7M | −22K (−1%) | 8 of 8 | |
| 7 | ![]() RIGL Rigel Pharmaceuticals Inc | $88.8M | 3.2% | 1.8M | No change | 8 of 8 | |
| 8 | ![]() INSP Inspire Med Sys Inc | $83.7M | 3.0% | 1.2M | −725K (−38%) | 7 of 8 | |
| 9 | ![]() ERAS Erasca Inc | $74.9M | 2.7% | 5.1M | +2.4M (+89%) | 7 of 8 | |
| 10 | ![]() BBNX Beta Bionics Inc | $71.1M | 2.5% | 3.7M | −650K (−15%) | 7 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
![]() GMED Globus Med Inc | $37M | 469K |
![]() SUPN Supernus Pharmaceuticals Inc | $24.2M | 520K |
![]() LIVN Livanova PLC | $21M | 255K |
![]() SYRE Spyre Therapeutics Inc | $13.1M | 147K |
![]() ALNY Alnylam Pharmaceuticals Inc | $9.9M | 33K |
🔒 Free account: see all 27.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Soleus Capital Management 13F FAQ
What does Soleus Capital Management own?
Soleus Capital Management reported 97 stocks worth $2.8B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are KRYS (13.5%), PODD (8.0%) and NVCR (5.3%). The table above lists every position in the filing (the top 10 without an account).
What did Soleus Capital Management buy and sell in Q3 2026?
Compared with Q2 2026: 27 new positions, 28 added to, 36 trimmed and 27 sold out. New positions include ZLAB, KOD and INBX. It sold all of GMED, SUPN and LIVN.
When will Soleus Capital Management file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Soleus Capital Management's portfolio worth?
The Q3 2026 filing reports $2.8B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.

























